skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 164,972  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Refined by: subject: Metastasis remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study
Material Type:
Article
Add to My Research

Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study

BMC cancer, 2021-09, Vol.21 (1), p.1-1045, Article 1045 [Peer Reviewed Journal]

COPYRIGHT 2021 BioMed Central Ltd. ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-021-08766-9 ;PMID: 34556087

Full text available

2
Heterogeneity of cancer‐associated fibroblasts: Opportunities for precision medicine
Material Type:
Article
Add to My Research

Heterogeneity of cancer‐associated fibroblasts: Opportunities for precision medicine

Cancer science, 2020-08, Vol.111 (8), p.2708-2717 [Peer Reviewed Journal]

2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1347-9032 ;ISSN: 1349-7006 ;EISSN: 1349-7006 ;DOI: 10.1111/cas.14537 ;PMID: 32573845

Full text available

3
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Material Type:
Article
Add to My Research

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Molecular cancer, 2023-08, Vol.22 (1), p.1-138, Article 138 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-023-01827-6 ;PMID: 37596643

Full text available

4
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Material Type:
Article
Add to My Research

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Journal of experimental & clinical cancer research, 2019-06, Vol.38 (1), p.255-255, Article 255 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1756-9966 ;ISSN: 0392-9078 ;EISSN: 1756-9966 ;DOI: 10.1186/s13046-019-1259-z ;PMID: 31196207

Full text available

5
PD-1 blockade inhibits osteoclast formation and murine bone cancer pain
Material Type:
Article
Add to My Research

PD-1 blockade inhibits osteoclast formation and murine bone cancer pain

The Journal of clinical investigation, 2020-07, Vol.130 (7), p.3603-3620 [Peer Reviewed Journal]

COPYRIGHT 2020 American Society for Clinical Investigation ;COPYRIGHT 2020 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Jul 2020 ;2020 American Society for Clinical Investigation 2020 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci133334 ;PMID: 32484460

Full text available

6
Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
Material Type:
Article
Add to My Research

Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting

Cell proliferation, 2021-10, Vol.54 (10), p.e13115-n/a [Peer Reviewed Journal]

2021 The Authors. Published by John Wiley & Sons Ltd. ;2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0960-7722 ;EISSN: 1365-2184 ;DOI: 10.1111/cpr.13115 ;PMID: 34464477

Full text available

7
The Tumor Microenvironment of High Grade Serous Ovarian Cancer
Material Type:
Book
Add to My Research

The Tumor Microenvironment of High Grade Serous Ovarian Cancer

https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode ;ISBN: 9783038975557 ;ISBN: 3038975559 ;ISBN: 9783038975540 ;ISBN: 3038975540 ;DOI: 10.3390/books978-3-03897-555-7

Full text available

8
Long non‑coding RNA GAS5 in human cancer (Review)
Material Type:
Article
Add to My Research

Long non‑coding RNA GAS5 in human cancer (Review)

Oncology letters, 2020-09, Vol.20 (3), p.2587-2594

COPYRIGHT 2020 Spandidos Publications ;COPYRIGHT 2020 Spandidos Publications ;Copyright Spandidos Publications UK Ltd. 2020 ;Copyright: © Yang et al. 2020 ;ISSN: 1792-1074 ;EISSN: 1792-1082 ;DOI: 10.3892/ol.2020.11809 ;PMID: 32782576

Full text available

9
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
Material Type:
Article
Add to My Research

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

BMC cancer, 2019-05, Vol.19 (1), p.494-494, Article 494 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-019-5675-4 ;PMID: 31126258

Full text available

10
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Material Type:
Article
Add to My Research

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Journal of hematology and oncology, 2019-05, Vol.12 (1), p.54-54, Article 54 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1756-8722 ;EISSN: 1756-8722 ;DOI: 10.1186/s13045-019-0738-1 ;PMID: 31151482

Full text available

11
Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT
Material Type:
Article
Add to My Research

Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT

Molecular cancer, 2019-03, Vol.18 (1), p.40-40, Article 40 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-019-0959-5 ;PMID: 30866952

Full text available

12
Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer
Material Type:
Article
Add to My Research

Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer

Molecular cancer, 2019-03, Vol.18 (1), p.68-68, Article 68 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-019-0972-8 ;PMID: 30927911

Full text available

13
Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway
Material Type:
Article
Add to My Research

Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway

Molecular cancer, 2019-02, Vol.18 (1), p.20-20, Article 20 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-018-0935-5 ;PMID: 30717751

Full text available

14
Classification of circulating tumor cells by epithelial-mesenchymal transition markers
Material Type:
Article
Add to My Research

Classification of circulating tumor cells by epithelial-mesenchymal transition markers

PloS one, 2015-04, Vol.10 (4), p.e0123976-e0123976 [Peer Reviewed Journal]

COPYRIGHT 2015 Public Library of Science ;COPYRIGHT 2015 Public Library of Science ;2015 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 Wu et al 2015 Wu et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0123976 ;PMID: 25909322

Full text available

15
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Material Type:
Article
Add to My Research

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Journal for immunotherapy of cancer, 2019-10, Vol.7 (1), p.278-278, Article 278 [Peer Reviewed Journal]

The Author(s). ;COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 2051-1426 ;EISSN: 2051-1426 ;DOI: 10.1186/s40425-019-0768-9 ;PMID: 31655605

Full text available

16
Nanotechnology in cancer diagnosis: progress, challenges and opportunities
Material Type:
Article
Add to My Research

Nanotechnology in cancer diagnosis: progress, challenges and opportunities

Journal of hematology and oncology, 2019-12, Vol.12 (1), p.137-137, Article 137 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1756-8722 ;EISSN: 1756-8722 ;DOI: 10.1186/s13045-019-0833-3 ;PMID: 31847897

Full text available

17
Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis
Material Type:
Article
Add to My Research

Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis

BMC cancer, 2020-07, Vol.20 (1), p.662-662, Article 662 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-020-07149-w ;PMID: 32677912

Full text available

18
Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance
Material Type:
Article
Add to My Research

Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance

Molecular cancer, 2020-05, Vol.19 (1), p.96-96, Article 96 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-020-01219-0 ;PMID: 32460771

Full text available

19
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance
Material Type:
Article
Add to My Research

EMT‐associated microRNAs and their roles in cancer stemness and drug resistance

Cancer communications (London, England), 2021-03, Vol.41 (3), p.199-217 [Peer Reviewed Journal]

2021 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center ;2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. ;2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2523-3548 ;EISSN: 2523-3548 ;DOI: 10.1002/cac2.12138 ;PMID: 33506604

Full text available

20
Long non-coding RNAs regulate drug resistance in cancer
Material Type:
Article
Add to My Research

Long non-coding RNAs regulate drug resistance in cancer

Molecular cancer, 2020-03, Vol.19 (1), p.54-13, Article 54 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-020-01162-0 ;PMID: 32164712

Full text available

Results 1 - 20 of 164,972  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (142,369)

Refine My Results

Creation Date 

From To
  1. Before 1965  (29)
  2. 1965 To 1981  (76)
  3. 1982 To 1995  (732)
  4. 1996 To 2010  (11,764)
  5. After 2010  (152,354)
  6. More options open sub menu

Subject 

  1. Science & Technology  (132,113)
  2. Life Sciences & Biomedicine  (120,386)
  3. Oncology  (73,155)
  4. Tumors  (71,661)
  5. Humans  (69,788)
  6. Cancer  (57,370)
  7. Cancer Therapies  (55,042)
  8. Medical Prognosis  (51,007)
  9. Patients  (50,394)
  10. Metastases  (44,792)
  11. Chemotherapy  (44,641)
  12. Breast Cancer  (38,178)
  13. Female  (35,962)
  14. Proteins  (33,570)
  15. Gene Expression  (29,579)
  16. Care And Treatment  (29,142)
  17. Male  (27,110)
  18. Prognosis  (26,681)
  19. Surgery  (25,487)
  20. More options open sub menu

Language 

  1. English  (163,562)
  2. Japanese  (17,409)
  3. Chinese  (1,052)
  4. Turkish  (406)
  5. Portuguese  (230)
  6. Spanish  (201)
  7. French  (185)
  8. German  (144)
  9. Norwegian  (103)
  10. Korean  (73)
  11. Polish  (67)
  12. Russian  (34)
  13. Persian  (19)
  14. Italian  (11)
  15. Romanian  (11)
  16. Dutch  (11)
  17. Catalan  (10)
  18. Latvian  (7)
  19. Ukrainian  (6)
  20. Slovenian  (5)
  21. More options open sub menu

Searching Remote Databases, Please Wait